Chemotherapy with Paclitaxel and Gemcitabine in Progressive Medullary and Thyroid Carcinoma of the Follicular Epithelium

Abstract

Nine patients (mean age 53) with metastasizing, progressive, medullary (MTC), thyroid carcinoma and progressive, nonradioiodine accumulating thyroid carcinoma of the follicular epithelium (follicular carcinoma, FTC and papillary carcinoma, PTC) were treated with a combination of paclitaxel and gemcitabine between 2004 and 2006. Tumors were histologically classified as follicular in 5 patients (56%), as papillary in 2 patients (22%), and medullary in 2 patients (22%). Paclitaxel (90–100 mg/m²) and gemcitabine (1 000 mg/m²) were applied for two, three, or 6 cycles every three weeks, depending on response and side effects. The effect of therapy was evaluated by radiographic imaging (CT images) and [¹⁸F]FDG-PET. All patients with papillary, follicular, or medullary thyroid carcinoma had continuous progression during restaging 14.8±8.8 weeks after initiation of chemotherapy, including one patient with stable disease after 3 cycles, but continuous progression after 6 cycles of chemotherapy. Paclitaxel and gemcitabine are not a valid chemotherapy option, in particular in patients with progressive, nonradioiodine-accumulating follicular thyroid carcinoma, who were already treated by other chemotherapeutic agents.

Key words

neoplasm - effect of therapy - malignant disease - endocrine tumor

References

• 1 Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JW, Wiersinga W. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium.  Eur J Endocrinol. 2006;  154 787-803
• 2 Mann K, Möller LC, Bockisch A, Quadbeck B, Schmid KW, Janssen OE. Chemotherapie beim Schilddrüsenkarzinom.  Onkologe. 2005;  11 78-86
• 3 Matuszczyk A, Petersenn S, Bockisch A, Gorges R, Sheu SY, Veit P, Mann K. Chemotherapy with doxorubicin in progressive medullary and thyroid carcinoma of the follicular epithelium.  Horm Metab Res. 2008;  40 210-213
• 4 Bockisch A, Brandt-Mainz K, Gorges R, Muller S, Stattaus J, Antoch G. Diagnosis in medullary thyroid cancer with [¹⁸F]FDG-PET and improvement using a combined PET/CT scanner.  Acta Med Austriaca. 2003;  30 22-25
• 5 Brandt-Mainz K, Muller SP, Gorges R, Saller B, Bockisch A. The value of fluorine-18 fluorodeoxyglucose PET in patients with medullary thyroid cancer.  Eur J Nucl Med. 2000;  27 490-496
• 6 Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG. New Guidelines to Evaluate the Response to Treatment in Solid Tumors European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.  J Natl Cancer Inst. 2000;  92 205-216
• 7 Young H, Baum R, Cremerius U, Herholz K, Hoekstra O, Lammertsma AA, Pruim J, Price P. Measurement of Clinical and Subclinical Tumour Response Using [¹⁸F]-fluorodeoxyglucose and Positron Emissions Tomography: Review and 1999 EORTC Recommendations.  Eur J Cancer. 1999;  35 1773-1782
• 8 Hoskin PJ, Harmer C. Chemotherapy for thyroid cancer.  Radiother Oncol. 1987;  10 187-194
• 9 Williams SD, Birch R, Einhorn LH. Phase II evaluation of doxorubicin plus cisplatin in advanced thyroid cancer: A Southeastern Cancer Study Group Trial.  Cancer Treat Rep. 1986;  70 405-407
• 10 Shimaoka K, Schoenfeld DA, DeWys WD, Creech RH, DeConti R. A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma.  Cancer. 1985;  56 2155-2160
• 11 Bonadonna G, Monfardini S, De Lena M, Fossati-Bellani F, Beretta G. Phase I and Preliminary Phase II Evaluation of Adriamycin.  Cancer Res. 1970;  30 2572-2582
• 12 Samonigg H, Hossfeld DK, Spehn J, Fill H, Leb G. Aclarubicin in advanced thyroid cancer: A phase II study.  Eur J Cancer Clin Oncol. 1988;  24 1271-1275
• 13 Scherübl H, Raue F, Ziegler R. Combination chemotherapy of advanced medullary and differentiated thyroid cancer. Phase II study.  J Cancer Res Clin Oncol. 1990;  116 21-23
• 14 Ekman ET, Lundell G, Tennvall J, Wallin G. Chemotherapy and multimodality treatment in thyroid carcinoma.  Otolaryngol Clin North Am. 1990;  23 523-527
• 15 Schlumberger M, Parmentier C. Phase II evaluation of mitoxantrone in advanced non anaplastic thyroid cancer.  Bull Cancer. 1989;  76 403-406
• 16 Suzumura K, Koike A, Naruse T, Matsumoto K, Nagata H, Kojima T, Kanemitsu T, Katoh K. Antitumor effect of UFT against differentiated thyroid cancer.  Gan To Kagaku Ryoho. 1994;  21 2485-2489
• 17 Zlock DW, Greenspan FS, Clark OH, Higgins CB. Octreotide therapy in advanced thyroid cancer.  Thyroid. 1994;  4 427-431
• 18 De Besi P, Busnardo B, Toso S, Girelli ME, Nacamulli D, Simioni N, Casara D, Zorat, Fiorentino MV. Combined chemotherapy with bleomycin, adriamycin, and platinum in advanced thyroid cancer.  J Endocrinol Invest. 1991;  14 475-480
• 19 Voigt W, Kegel T, Weiss M, Mueller T, Simon H, Schmoll HJ. Potential activity of paclitaxel, vinorelbine and gemcitabine in anaplastic thyroid carcinoma.  J Cancer Res Clin Oncol. 2005;  131 585-590
• 20 Ain KB, Tofiq S, Taylor KD. Antineoplastic activity of taxol against human anaplastic thyroid carcinoma cell lines in vitro and in vivo.  J Clin Endocrinol Metab. 1996;  81 3650-3653
• 21 Kaczirek K, Schindl M, Weinhäusel A, Scheuba C, Passler C, Prager G, Raderer M, Hamilton G, Mittlböck M, Siegl V, Pfragner R, Niederle B. Cytotoxic activity of camptothecin and paclitaxel in newly established continuous human medullary thyroid carcinoma cell lines.  J Clin Endocrinol Metab. 2004;  89 2397-2401
• 22 Yang HL, Pan JX, Sun L, Yeung SC. p21 Waf-1 (Cip-1) enhances apoptosis induced by manumycin and paclitaxel in anaplastic thyroid cancer cells.  J Clin Endocrinol Metab. 2003;  88 763-772
• 23 Ball DW, Jin N, Rosen DM, Dackiw A, Sidransky D, Xing M, Nelkin BD. Selective growth inhibition in BRAF mutant thyroid cancer by the mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244.  J Clin Endocrinol Metab. 2007;  92 4712-4718
• 24 Skinner MA, Safford SD, Freemerman AJ. RET tyrosine kinase and medullary thyroid cells are unaffected by clinical doses of STI571.  Anticancer Res. 2003;  23 3601-3606
• 25 Henderson YC, Fredrick MJ, Clayman GL. Differential responses of human papillary thyroid cancer cell lines carrying the RET/PTC1 rearrangement or a BRAF mutation to MEK1/2 inhibitors.  Arch Otolaryngol Head Neck Surg. 2007;  133 810-815
• 26 Ain KB, Lee C, Williams KD. Phase II trial of thalidomide for therapy of radioiodine-unresponsive and rapidly progressive thyroid carcinomas.  Thyroid. 2007;  17 663-670
• 27 Kundra P, Burman KD. Thyroid cancer molecular signaling pathways and use of targeted therapy.  Endocrinol Metab Clin North Am. 2007;  36 839-853
• 28 Chow LQ, Eckhardt SG. Sunitinib: from rational design to clinical efficacy.  J Clin Oncol. 2007;  25 884-896
• 29 Lopez JP, Wang-Rodriguez J, Chang C, Chen JS, Pardo FS, Aguilera J, Ongkeko WM. Gefitinib inhibition of drug resistance to doxorubicin by inactivating ABCG2 in thyroid cancer cell lines.  Arch Otolaryngol Head Neck Surg. 2007;  133 1022-1027
• 30 Vidal M, Wells S, Ryan A, Cagan R. ZD6474 suppresses oncogenic RET isoforms in a Drosophila model for type 2 multiple endocrine neoplasia syndromes and papillary thyroid carcinoma.  Cancer Res. 2005;  65 3538-3541
• 31 Schoenberger J, Grimm D, Kossmehl P, Infanger M, Kurth E, Eilles C. Effects of PTK787/ZK222584, a tyrosine kinase inhibitor, on the growth of a poorly differentiated thyroid carcinoma: an animal study.  Endocrinology. 2004;  145 1031-1038

Correspondence